Abstract
Objective There is growing evidence of, and biological plausibility for, elevated levels of high-density lipoprotein cholesterol (HDL-C), being related to lower rates of severe infection. Accordingly, we tested whether pre-pandemic HDL-C within the normal range is associated with subsequent COVID-19 hospitalisations and death.
Approach We analysed data on 317,306 participants from UK Biobank, a prospective cohort study, baseline data for which were collected between 2006 and 2010. Follow-up for COVID-19 was via hospitalisation records and a national mortality registry.
Results After controlling for a series of confounding factors which included health behaviours, inflammatory markers, and socio-economic status, higher levels of HDL-C were related to a lower risk of later hospitalisation for COVID-19. The effect was linear (p-value for trend 0.001) such that a 0.2 mmol/L increase in HDL-C was associated with a corresponding 9% reduction in risk (odds ratio; 95% confidence interval: 0.91; 0.86, 0.96). A very similar pattern of association was apparent when COVID-19 mortality was the outcome of interest (odds ratio per 0.2 mmol/l increase in HDL-C: 0.90; 0.81, 1.00); again, a stepwise effect was evident (p-value for trend 0.03).
Conclusions These novel results for HDL-C and COVID-19 events warrant testing in other studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CL is supported by the Beatriu de Pinos postdoctoral programme of the Government of Catalonia's Secretariat for Universities and Research of the Ministry of Economy and Knowledge (2017-BP-00021); GDB is supported by the Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1); MH through a joint award from the Economic Social Research Council and Medical Research Council (RES-579-47-0001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by the North-West Multi-centre Research Ethics Committee (11/NW/0382; 16/NW/0274).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
classale{at}imim.es, m.hamer{at}ucl.ac.uk, alvaro.hernaez1{at}gmail.com, crg{at}mrc.soton.ac.uk, david.batty{at}ucl.ac.uk
Conflict of interest: None.
Funding: CL is supported by the Beatriu de Pinós postdoctoral programme of the Government of Catalonia’s Secretariat for Universities and Research of the Ministry of Economy and Knowledge (2017-BP-00021); GDB by the Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1); and MH through a joint award from the Economic Social Research Council and Medical Research Council (RES-579-47-0001).
Data Availability
Data sharing: Data from UK Biobank (https://www.ukbiobank.ac.uk/) are available to bona fide researchers on application. Part of this research has been conducted using the UK Biobank Resource under Application 10279.
